OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section

Gene Section Review

Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10) 854

Atlas of Genetics and Cytogenetics in Oncology and Haematology

OPEN ACCESS JOURNAL AT INIST-CNRS

PTK2 (PTK2 protein tyrosine kinase 2) Joerg Schwock, Neesha Dhani

Department of Laboratory Medicine and Pathobiology, Division of Anatomical Pathology, University of Toronto, 1 King's College Circle, 6th Floor, Toronto, Ontario M5S 1A8, Canada (JS); University Health Network, Princess Margaret Hospital, Division of Medical Oncology and Hematology and Institute of Medical Sciences, University of Toronto, Princess Margaret Hospital/Ontario Cancer Institute, 610 University Ave., Room: 7-113, Toronto, Ontario M5G 2M9, Canada (ND)

Published in Atlas Database: March 2011

Online updated version : http://AtlasGeneticsOncology.org/Genes/PTK2ID41898ch8q24.html DOI: 10.4267/2042/46033

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity Other names: FADK; FAK; FAK1; FRNK; pp125FAK

HGNC (Hugo): PTK2

Location: 8q24.3

DNA/RNA Note Cloning of the FAK cDNA and initial characterization of the kinase was accomplished independently by three groups in 1992 (Schaller et al., 1992; Hanks et al., 1992; Guan and Shalloway 1992). The cDNA of the human FAK homologue was first cloned by André and Becker-André (1993). The position of the human PTK2 gene encoding FAK on chromosome 8 was first predicted by Fiedorek and Kay (1995).

Transcription Initial expression studies using reverse transcriptase PCR detected FAK mRNA in a series of lymphoid cell lines as well as HeLa and SK-N-SH neuroblastoma cells indicating ubiquitous expression. Only a lymphocyte adhesion deficient cell line tested negative for the FAK transcript (André and Becker-André 1993). Transcripts of different sizes were detected in different human tissues in the same study with differential expression patterns for these transcripts noted in brain, lung, heart, liver and placenta.

Several transcript variants encoding different FAK isoforms have been found for the PTK2 gene. The full-length nature of the following three has been determined. (Sources: http://useast.ensembl.org/ index.html; http://www.ncbi.nlm.nih.gov/pubmed/) - Variant 1 differs in the 5' UTR and coding sequence compared to variant 2. The resulting isoform (a) is shorter at the N-terminus compared to isoform (b). 4414 bp - 33 exons - 1065 aa. Ave. residue weight: 113.521. Charge: 3.5. Isoelectric point: 6.7311. Molecular weight: 120899.54. Number of residues: 1065. - Variant 2 encodes the longest isoform (b). 4286 bp - 31 exons - 1073 aa. Ave. residue weight: 113.366. Charge: 2.0. Isoelectric point: 6.6317. Molecular weight: 121641.45. Number of residues: 1073. - Variant 3 differs in the 5' UTR and coding sequence, and contains two additional in-frame segments near the 3' end of the coding sequence, compared to variant 2. The resulting isoform (c) is shorter at the N-terminus and contains two additional segments in the C-terminus compared to isoform b.

Protein Note Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase which was isolated for the first time by co-immunoprecipitation of tyrosine-phosphorylated proteins from cells transformed with Rous sarcoma virus v-Src (Kanner et al., 1990).

PTK2 (PTK2 protein tyrosine kinase 2) Schwock J, Dhani N


Figure 1: Schematic of focal adhesion kinase domain structure with phosphorylation sites.

Description FAK is a ubiquitously expressed protein composed of a N-terminal FERM domain (protein 4.1, ezrin, radixin, moesin), a kinase domain, three intervening proline-rich regions (PRR) and a C-terminal focal adhesion targeting (FAT) domain (Figure 1).

Expression Ubiquitous.

Localisation Cytoplasmic and nuclear.

Function FAK is characterized by a functional duality, serving as a kinase as well as a molecular scaffold. These two functions may be required independently or in concert depending on the context in which FAK-mediated signaling occurs (Sieg et al., 1999; Sieg et al., 2000). FAK regulates the dynamic of focal adhesion complexes which are sites of attachment between cells and extracellular matrix. Cyclic assembly and disassembly of these complexes at the leading and trailing edge of the cell is required for the migration of mesenchymal cells and those that adopt mesenchymal-like characteristics as a consequence of developmental processes or during disease states. The latter mainly encompasses forms of tissue repair (i.e. wound healing and fibrosis) as well as neoplasia (i.e. tumor invasion and metastasis). As an example, Figure 2 shows immunohistochemical staining for FAK in metastatic cancer of the uterine cervix. FAK has been implicated with the establishment of a front-back polarity (Tilghman et al., 2005), lamellipodial persistence at the leading edge (Owen et al., 2007) and release of adhesions at the trailing edge (Iwanicki et al., 2008). Integrin engagement with the extracellular matrix results in integrin clustering and a sequence of inter- and intramolecular events that permit the autophosphorylation of FAK at Tyr397 (Dunty et al., 2004). Subsequent recruitment of Src-family kinases through SH2-domain binding is followed by a mutual activation of both kinases. In the case of FAK this further activation is accomplished by phosphorylation of other tyrosine residues, specifically Tyr407, 576, 577, 861 and 925. Phosphorylation of Tyr576 and 577 increases FAK kinase activity whereas the remaining tyrosine residues serve as docking sites for SH2-containing factors such as Grb2 which links FAK into the MAPK pathway. Tyr397 also constitutes a docking

site for the p85 subunit of PI3K (Chen and Guan, 1994) and phospholipase C gamma (Zhang et al., 1999). The PRRs are sites of interaction with SH3-containing factors which transmit signals downstream of the kinase and regulate the activity of Rho-family GTPases in charge of cell motility through the formation of stress fibres (RhoA), lamellipodia (Rac) and filopodia (Cdc42). Crk-associated substrate (p130Cas), initially identified in a two-hybrid screen, is one of the main downstream factors that bind to the PRRs of FAK (Polte and Hanks, 1995). Signaling via p130Cas towards Crk, DOCK180 and Rac has been linked to membrane ruffling, lamellipodia formation and cell motility (Harte et al., 1996; Cho and Klemke, 2002). A second essential downstream target of FAK is paxillin (Bellis et al., 1995), an adaptor protein lacking intrinsic kinase activity which can be phosphorylated at two sites, Tyr31 and Tyr118, and binds FAK within the C-terminal focal adhesion targeting (FAT) region (Hayashi et al., 2002). Mutations in FAK that disrupt binding to paxillin affect the localization of the kinase to focal contacts. Paxillin may also be involved in regulation of MAPK downstream signaling due to an overlapping binding site with Grb2 which binds to Tyr925 within the FAT region (Liu et al., 2002). More recent studies link FAK to the regulation of cell-cell contacts, microtubule stability and control of gene transcription. Conflicting results have been reported from different experimental systems implicating FAK either with the dissolution (Avizienyte et al., 2002; Cicchini et al., 2008) or the promotion (Yano et al., 2004; Playford et al., 2008) of cell-cell contacts which suggests a dependency of this feature on the specific cellular context. Ezratty et al. (2005) reported on the role of FAK, Grb2 and dynamin in microtubule-induced focal adhesion disassembly. Earlier studies demonstrated an integrin-mediated activation of FAK at the leading edge of migrating cells as requirement for microtubule stabilization mediated by Rho and mDia (Palazzo et al., 2004). This mechanism also involves localization of a lipid raft marker, ganglioside GM1, to the leading edge. Xie et al. (2003) showed that Cdk5-mediated serine-phosphorylation of FAK was linked to the localization of the kinase at microtubule fork structures which contribute to nuclear repositioning in migrating neuronal cells. Recently, serine-phosphorylated FAK was shown to co-localize with centrosomes in mitotic endothelial cells. In this study by Park et al. (2009), FAK was also found



Figure 2: Immunohistochemical staining of FAK in invasive cancer of the uterine cervix. (Note the accentuation of the FAK staining at the margin of the tumor nests. Size bar, 1 mm). Method and antibody: Schwock et al., 2009.

associated with cytoplasmic dynein, and deletion of FAK resulted in mitotic defects. In 2005, Golubovskaya et al. reported results indicating a physical interaction between the N-terminal fragment of FAK and the N-terminal transactivation domain of p53. This interaction led to suppression of p53-mediated apoptosis and inhibition of the transcriptional activity of p53. Lim et al. (2008) subsequently provided data demonstrating a scaffolding role of nuclear FAK for MDM2-mediated p53 degradation mediated by the different lobes of the FERM domain. Also, basic sequences in the F2 lobe of the FERM domain were implicated in the nuclear localization of FAK (Lim et al., 2008), but alternative mechanisms independent from this putative nuclear localization signal are thought to exist (Schaller, 2010). Another nuclear function was recently uncovered by Luo et al. (2009) who described a role of FAK in chromatin remodelling via its interaction with MBD2 leading to increased myogenin expression and muscle-terminal differentiation. Liu et al. (2004), Li et al. (2004) and Ren et al. (2004) reported an involvement of FAK in netrin-1 signaling downstream of the netrin receptor DCC with consequences for axonal outgrowth and guidance in the developing brain. - Mouse Models Several mouse models have been generated to elucidate the functions of FAK both during normal development and neoplasia. A role of FAK in embryonal development was first observed in fak-/- mice which displayed defects in mesoderm development and anterior-posterior axis formation with embryonic lethality around day E8.5 (Ilic et al., 1995).

A conditional knockout model using a Cre-loxP system with Cre recombinase under the control of the nkx2-5 promoter was generated by Hakim et al. (2007). The major abnormality reported from this study was a profound disturbance of the development of the cardiac outflow tract. Knockout mice from this study died shortly after birth and displayed a range of cardiac defects which resemble the human congenital heart defects Tetralogy of Fallot and persistent truncus arteriosus. Peng et al. (2006) and DiMichele et al. (2006) reported results obtained with conditional knockout mice which carried Cre-recombinase under the control of the myosin light chain 2v promoter. Peng et al. (2006) found that knockout mice developed eccentric cardiac hypertrophy upon stimulation with angiotensin II or pressure overload. In contrast, the results by DiMichele et al. (2006) suggest that FAK functions to promote cardiac hypertrophy. In a later study by Peng at al. (2008) with myosin light chain-2a Cre mice they observed cardiac developmental abnormalities with thin ventricular walls and ventricular septal defects in the knockout mice, the majority of which died in the embryonic stage. Endothelial cell-specific knockout of FAK, again using a Cre-loxP approach, has been reported by Shen et al. (2005) and Braren et al. (2006). The observed phenotypes in knockout mice from both studies strongly suggest a role of FAK in vascular morphogenesis, particularly vascular remodelling and sprouting angiogenesis. The roles of FAK in the cardiovascular system were reviewed by Vadali et al. (2007).



Figure 3: Schematic of the Cellular Functions of FAK.

A series of mouse models suggest an essential role of FAK during the development of the central nervous system. Beggs et al. (2003) created dorsal forebrain-specific conditional knockout mice using the Cre/loxP approach and observed an essential function of FAK for the formation of a normal basal lamina at the interface between radial glial end-feet and meningeal fibroblasts. They noted that the cortical changes seen in their study resembled lissencephaly phenotypes seen in some forms of human congenital muscular dystrophy. Van Miltenburg et al. (2009) investigated the role of FAK in normal mammary gland using a conditional FAK-knockout mammary epithelial cell transplantation model based on FAK(lox/lox)/Rosa26Cre-ERT2 donor mice with loss of FAK in all mammary cells. They observed an abnormal mammary duct development with a disruption of myoepithelial and luminal epithelial cell layer and aberrant ductal morphogenesis during pregnancy. Comprehensive reviews focused on the cellular functions of FAK have been published by Mitra et al. (2005) and Schaller (2010). Figure 3 schematically summarizes some of the diverse cellular functions of FAK. - Regulation The level of FAK expression is negatively and positively regulated by several transcription factors including p53, NF-kB and N-Myc (Golubovskaya et al., 2004; Beierle et al., 2007). Aside from the tyrosine residues implicated with FAK activation, at least four different serine phosphorylation sites (Ser722, 840, 843 and 910) have been recognized within FAK. Although the function of these serine sites has been examined

less comprehensively, their phosphorylation has generally been associated with FAK inactivation, such as during mitosis (Ma et al., 2001), in suspension and under conditions that disturb the integrity of the actin cytoskeleton (Jacamo et al., 2007). FAK signaling is subject to additional levels of regulation which involve proteolytic cleavage (Dourdin et al., 2001), sumoylation (Kadaré et al., 2003), inhibition by FAK family interacting protein of 200 kDa (FIP200) (Abbi et al., 2002), dephosphorylation by protein-tyrosine phosphatases (Zeng et al., 2003), and generation of alternatively spliced isoforms such as FAK-related non-kinase (FRNK) (Schaller et al., 1993). - Other protein family members: Pyk2.

Homology

% Identity for : Homo sapiens PTK2

Protein DNA

vs. Pan troglodytes PTK2 99.8 99.7

vs. Canis lupus familiaris PTK2 97.0 91.7

vs. Mus musculus Ptk2 97.2 90.7

vs. Rattus norvegicus Ptk2 97.0 90.8

vs. Gallus gallus PTK2 94.9 83.9

vs. Danio rerio ptk2.1 83.2 74.2

vs. Drosophila melanogaster Fak56D

42.9 48.9

vs. Caenorhabditis elegans kin-32

36.5 47.8

(Source : http://www.ncbi.nlm.nih.gov/pubmed/)



Implicated in Neoplasia Note Increased expression of FAK was first noticed in high-grade and metastatic sarcomas (Weiner et al., 1994) and later in pre-invasive as well as invasive epithelial neoplasms (Owens et al., 1995). In general, lower levels of FAK expression are found in normal tissues whereas the higher levels are present in metastatic cancer suggesting an involvement of the kinase in oncogenesis. In neoplastic conditions the kinase has been credited with a range of functions including tumor cell motility (Sieg et al., 1999), matrix degradation leading to distant spread (Hauck et al., 2002), suppression of apoptosis (Sonoda et al., 2000), anoikis (Frisch et al., 1996) and senescence (Pylayeva et al., 2009) as well as positive effects on angiogenesis (Mitra et al., 2006), vasculogenic mimicry (Hess et al., 2005) and hypoxia response (Skuli et al., 2009). Results from a Cre/loxP-mediated FAK-knockout model specific to mouse mammary epithelial cells revealed a reduced pool of cancer stem/progenitor cells after FAK deletion which suggests that the kinase may not only support tumor cell dissemination to distant sites, but also the colonization of the target organ and establishment of a new tumor mass (Luo et al., 2009). Other transgenic mouse models focused on the role of FAK in neoplasia have been reported by McLean et al. (2004) for skin and by Lahlou et al. (2007), Provenzano et al. (2008) and Pylayeva et al. (2009) for mammary tumor formation and progression.

Nervous system Note The role of FAK in glioma tumor progression and in the regulation of the permeability of tumor-associated vasculature has been described, as well as the therapeutic efficacy of FAK inhibition by both pharmacologic compounds and liposomal-mediated RNA interference (Shi et al., 2007; Lipinski et al., 2008; Lee et al., 2010; Wang et al., 2011). Immunohistochemical analysis of 96 patient biopsies demonstrated higher levels of total and phosphorylated FAK in high grade tumors which correlated with inferior patient survival (Ding et al., 2010). Beierle et al. (2007) reported on the relevance of FAK as cellular survival factor in N-myc-amplified neuroblastoma and identified N-myc binding sites in the FAK promoter. Recently, the same group also provided data indicating greater in vivo-therapeutic efficacy of pharmacologic FAK inhibition in N-myc-positive model systems (Beierle et al., 2010a; Beierle et al., 2010b). Efficacy of a novel small molecule dual IGF1R/FAK tyrosine kinase inhibitor (TAE226) leading to decreased FAK phosphorylation and cellular viability, cell cycle arrest and apoptosis has been described in human neuroblastoma cell lines (Beierle et

al., 2008b). FAK expression was demonstrated in 51 of 70 clinical neuroblastoma samples by immunohistochemistry. FAK protein levels correlated with mRNA transcript levels and with advanced disease stage in this study (Beierle et al., 2008a).

Head and neck squamous cell carcinoma Note FAK has been linked to invasion in squamous cell carcinoma of the head and neck through promotion of cell motility and MMP-2 production (Canel et al., 2008). FAK gene and protein expression were previously evaluated in 211 clinical samples which included tissue from cases of dysplasia and benign hyperplasia (Canel et al., 2006). In this study, 62% of the primary cancers had high FAK protein expression, and the levels were consistent with those seen in corresponding lymph node metastases. A recent preclinial study has implicated FAK phosphorylation levels with radioresistance (Hehlgans et al., 2009).

Thyroid carcinoma Note Immunohistochemical staining of 108 patient samples for FAK protein discriminated malignant from benign thyroid lesions. FAK levels correlated with tumor size and capsular/lymphatic invasion (Michailidi et al., 2010). Previously, Kim et al. (2004) reported FAK expression in follicular, papillary, medullary and anaplastic thyroid carcinomas. FAK was not expressed in normal thyroid tissue and nodular hyperplasia, but in some of the follicular adenomas included in their study.

Breast cancer Note Lahlou et al. (2007) reported a block in tumor progression in a transgenic mouse model of breast cancer with disrupted FAK function based on Cre/loxP recombination. An earlier immunohistochemical study on clinical breast tissue showed increased FAK expression in ductal carcinoma in situ compared to atypical ductal hyperplasia and invasive ductal carcinoma (Lightfoot et al., 2004). The authors of this study concluded that FAK overexpression precedes tumor cell invasion and metastasis. Subsequently, a study by Lark et al. (2005) in 629 breast cancer samples correlated high FAK protein expression with poor prognostic indicators such as high mitotic index and nuclear grade, negative hormone receptor status, and Her2/neu over-expression. Schmitz et al. (2005) provided further evidence to support Her2/neu downstream signaling through FAK/Src-mediated pathways. Recently, a positive correlation between FAK over-expression and p53 mutation status has been reported (Golubovskaya et al., 2008; Golubovskaya et al., 2009). Yom et al. (2010) evaluated 435 cases of invasive ductal cancer for FAK gene copy number by fluorescence in situ hybridization (FISH) and FAK



protein expression by immunohistochemistry, both of which correlated with features of aggressive tumor biology. Concordance between FISH and immunohistochemistry results was observed in 74.9%. An increased gene copy number by FISH correlated significantly with inferior patient outcome in this study.

Lung cancer Note Array comparative genomic hybridization studies on clinical samples of small cell lung cancer demonstrated regions of copy number alternations (gains and losses) enriched for genes involved in focal adhesion signaling. This included gains of FAK copy number which was confirmed in a smaller subset of the original 46 cases by FISH and quantitative RT-PCR. FAK was also highly expressed in tumor tissue (90% of 52 samples) in comparison with normal lung samples (Ocak et al., 2010). Wang et al. (2009) reported results of their study focused on FAK expression in bronchio-alveolar carcinoma (BAC) and lung adenocarcinomas. They found that in lung adenocarcinoma overall survival was better for patients with FAK-negative compared with FAK-positive tumors. A study by Hiratsuka et al. (2011) implicated endothelial FAK and E-selectin with the formation of lung metastasis from distant primary tumors due to the formation of discrete foci of vascular hyper-permeability important for the initial homing of metastatic cancer cells to the lungs.

Gastro-intestinal tract cancer Note Giaginis et al. (2009) reported results of an immunohistochemical study performed on the two major subtypes of gastric adenocarcinoma, including 30 cases of intestinal- and 36 cases of diffuse-type. Although FAK staining in diffuse-type gastric cancer correlated with larger tumor size and advanced disease stage, it also correlated with longer overall survival. For intestinal type cancer, however, an association with increased proliferative capacity and a non-significant trend to inferior survival was reported. A retrospective study including 444 surgical samples demonstrated a positive correlation between FAK gene amplification and protein expression levels with tumor size, lymphovascular invasion and nodal/distant metastases (Park et al., 2010). Focal adhesion kinase protein expression and gene amplification were positively correlated with each other in this study, and each of them was found to be an independent poor prognostic factor. FAK has been implicated in invasion and metastasis as well as chemoresistance in pancreatic cancer (Duxbury et al., 2003; Duxbury et al., 2004). FAK overexpression by immunohistochemistry, demonstrated in 24 of 50 (48%) patient samples, correlated with tumor size, but no other features including grade, lymph node involvement or metastasis in a study by Furuyama et al. (2006). Another study included an examination of both

FAK and Src protein levels. FAK expression correlated significantly with tumor stage while Src expression correlated with both tumor stage and patient survival, and was identified as an independent prognostic factor by multivariate analysis (Chatzizacharias et al., 2010). Hayashi et al. (2010) demonstrated high levels of cytoplasmic FAK expression in normal biliary epithelium and observed a gradual loss of staining from dysplasia to extra-hepatic bile duct carcinoma. In this study, positive FAK staining was associated with a significantly better survival. Increased levels of FAK mRNA and protein have also been observed in a study of 60 patients with hepatocellular cancers. Increased mRNA levels correlated with tumor size, serum AFP and inferior disease-free and overall survival (Fujii et al., 2004). RNA interference studies in colorectal cancer cell line xenografts demonstrated that FAK inhibition resulted in inhibition of cell proliferation and angiogenesis, induction of apoptosis and tumor growth suppression (Lei et al., 2010). Elevated levels of FAK mRNA and protein were noted in a small cohort of 34 matched primary colon cancers and liver metastases (Lark et al., 2003). More recently a larger series of colorectal cancers with matched liver metastases was used to evaluate the correlation of FAK staining with clinical outcome. In this study, FAK staining was equivalent in primary and metastatic lesions, and elevated levels of FAK and Src were associated with a reduced time to recurrence (de Heer et al., 2008).

Female genital tract cancer Note FAK has been implicated in the invasive and metastatic phenotype of ovarian cancer through multiple pathways (Hu et al., 2008; Yagi et al., 2008). In one report, MUC4-induced epithelial-mesenchymal transition was partially mediated by FAK, and pharmacologic FAK inhibition successfully abrogated MUC4-induced cell motility (Ponnusamy et al., 2010). In another study, cooperative signaling of c-met and alpha5beta1 integrin through FAK/Src was associated with promotion of invasion and metastases (Mitra et al., 2010). FAK activation also appears to be relevant to the development of resistance to standard cytotoxics (Halder et al., 2005; Villedieu et al., 2006) and preclinical studies have demonstrated therapeutic efficacy of various methods of FAK inhibition including pharmacologic inhibition and RNA interference (Halder et al., 2006; Halder et al., 2007; Yang et al., 2007). Sood et al. (2010) recently described protection from anoikis by catecholamine signaling mediated by FAK. They concluded that these results support a role for FAK signaling in the stress-mediated promotion of aggressive tumor biology. They also demonstrated increased levels of FAK and phosphorylated FAK in greater than 50% of the examined tumors, both of which correlated with inferior patient survival. Two earlier studies



documented up-regulation of FAK protein and phosphorylated FAK in invasive ovarian cancers in comparison with normal epithelium (Sood et al., 2004; Grisaru-Granovsky et al., 2005). Sood et al. (2004) also noted associations between FAK immunohistochemical staining and more advanced tumor stage, tumor grade, metastasis and inferior overall survival. Immunohistochemical analysis of 134 cases of endometrial cancer demonstrated moderate to strong staining in the majority (89%) of cases. Weak FAK staining was noted in the remaining 11% and associated with a trend to improved survival. Increased FAK staining, however, correlated with measures of poor outcome including tumor grade, lymphovascular invasion and lymph node metastases (Gabriel et al., 2009). A different study demonstrated high levels of FAK expression in endometrial cancers of different histologies (endometrioid, serous and clear cell) as well as in regions of endometrial hyperplasia. The authors concluded that their data implicate FAK in endometrial carcinogenesis (Livasy et al., 2004). An analysis of 166 surgical samples demonstrated cytoplasmic and membranous FAK staining in regions of cervical dysplasia and frankly invasive cancer of the uterine cervix with absent staining in adjacent normal cervical epithelium (Gabriel et al., 2006). One third of the patients, with tumors exhibiting weak FAK staining, had an inferior survival compared to those with moderate/strong FAK staining, and weak FAK staining correlated with lymph node positivity in this study. Oktay et al. (2003) demonstrated positive FAK staining in premalignant lesions. Similarly, Schwock et al. (2009) demonstrated an increase in FAK expression and concurrent decrease of E-cadherin in metastatic cervical cancer and carcinoma in-situ compared to normal cervical epithelium. An association between E-cadherin loss and FAK was also noted in an earlier study that included 26 carcinomas and 5 carcinoma in situ cases (Moon et al., 2003). Although FAK protein expression remained constant in this study, elevated levels of phosphorylated FAK were found in carcinoma samples.

Male genital tract cancer Note FAK has been linked with aggressive tumor behavior in models of androgen-independent prostate cancer (Johnson et al., 2008). An early study comparing normal and hyperplastic prostatic tissue with localized and advanced prostate cancers demonstrated increased levels of total and activated FAK in more advanced disease (Tremblay et al., 1996). Association of FAK with paxillin and p50csk was noted in cases of metastatic cancer. Rovin et al. (2002) described increased FAK expression in pre-malignant lesions that was maintained at different stages of tumor progression. A study by Zheng et al. (1999) proposed that the migratory behavior of prostate cancer cells is

related to the de novo expression of alphaVbeta3 integrin with signaling through FAK.

Genito-urinary tract cancer Note Increased levels of FAK and paxillin mRNA transcript have been noted in metastasizing renal carcinoma cell lines in comparison with normal renal cortex epithelial cells (Jenq et al., 1996). FAK/Src signaling was also demonstrated to be relevant to the aggressive behavior of bladder carcinoma cells in vitro, and inhibition of the phosphatase HD-PTP resulted in an enhanced FAK phosphorylation and increased cell motility (Mariotti et al., 2009).

Skin cancer Note Preclinical studies have implicated FAK with the promotion of an aggressive melanoma phenotype through its effects on invasion and migration (Hess et al., 2005; Hess and Hendrix 2006; Smit et al., 2007; Kaneda et al., 2008; Sun et al., 2009). FAK also has importance early in the metastatic dissemination of melanoma cells (Abdel-Ghany et al., 2002). A study by Smith et al. (2005) demonstrated that downregulation of FAK by antisense oligonucleotide sensitizes melanoma cells to 5-fluorouracil treatment. A preliminary clinical report suggests that FAK may function as a universal tumor-associated antigen that could be exploited for cancer immunotherapy including melanoma (Kobayashi et al., 2009). A recent study by Trimmer et al. (2010) reported reduced levels of caveolin-1 in clinical metastases of melanoma as well as in highly metastatic melanoma cell lines. They demonstrated that caveolin-1 expression in B16F10 melanoma cells promotes cell proliferation while suppressing invasion and migration via FAK/Src. McLean et al. (2004) demonstrated a role for FAK in the malignant progression from papilloma to squamous cell carcinoma in a transgenic mouse model combined with chemical carcinogenesis. No effect of the FAK deletion was noted on wound re-epithelialization.

Soft tissues, bone and hemato-lymphoid tissues Note Yui et al. (2010) developed a highly metastatic osteosarcoma cell line through in vivo selection which, in comparison with the parental line, demonstrated higher levels of activated FAK and cdc42. Hanada et al. (2005) showed localization of phosphorylated FAK at the infiltrative edge in a three dimensional culture model using invasive murine fibrosarcoma cells. In the same study, expression of FAK-related non-kinase (FRNK) inhibited experimental metastases in syngenic mice without significant effects on primary tumor growth. In a study on bone metastasis, the dual FAK/Pyk2 inhibitor PF-271 suppressed the growth of



experimental intra-tibial tumors in rats and restored tumor-induced bone loss (Bagi et al., 2008). Immunohistochemical analysis of normal and neoplastic hemato-lymphoid tissues demonstrated FAK staining in B cells of the germinal center, marginal and mantle zones (Ozkal et al., 2009). Corresponding staining was present in most B-cell lymphomas while T-cell lymphomas were predominantly negative. Neoplastic cells of classical Hodgkin's lymphoma were negative for FAK while those of lymphocyte-predominant Hodgkin's lymphoma were positive in the same study. A study of 60 primary acute myeloid leukemia samples demonstrated FAK transcript and protein expression in 48% cases and Pyk2 expression in 81% cases (Recher et al., 2004). FAK-positive acute myeloid leukemia cells displayed a higher migratory efficiency and lower sensitivity to chemotherapy. FAK expression positively correlated with white blood count at diagnosis, death rate and median survival.

Non-neoplastic disorders Note Shahrara et al. (2007) reported on the elevated expression of phosphorylated FAK, Pyk2 and other signaling molecules, in synovial tissues of patients with rheumatoid or osteoarthritis. They postulated that FAK signaling may be important for the recruitment of inflammatory cells into susceptible joints and required to promote the disease process. Chen et al. (2001) found that keratinocytes from patients with psoriasis have elevated levels of phosphorylated FAK and concluded that integrin/FAK signaling contributes to a 'pre-activation' of uninvolved keratinocytes that predisposes to the development of psoriatic plaques in response to certain stimuli. FAK has a role in the development of the cardiovascular system since FAK-null mice are embryonically lethal with phenotypic abnormalities approximating those seen in human congenital heart defects (Vadali et al., 2007). FAK also appears to be involved cardiac hypertrophy and heart failure through its involvement in the cardiac response to biochemical stress and hypertrophic agonists. The relevance of FAK to cardiac physiology likely differs with the cellular context. Although FAK activation has been suggested to accelerate function deterioration of an overloaded heart, selective FAK deletion in cardiomyoctes has also been associated with maladaptive cardiac remodeling (Franchini et al., 2009). FAK appears to be essential for normal glucose transport and glycogen synthesis due to cross talk between integrin and insulin signaling pathways (Huang et al., 2002; Huang et al., 2006). FAK has also been implicated in hyperglycemia-related vascular complications in Diabetes mellitus (Mori et al., 2002). Two independent studies reported on increased levels

of activated FAK in the glomeruli from diabetic rats that could be abrogated by insulin treatment (Clark et al., 1995; Shikano et al., 1996). FAK signaling has been implicated with non-neoplastic renal disease. Holzapfel et al. (2007) documented a role for FAK during restoration of tubular integrity in renal ischemia and reperfusion, and an earlier study by Morino et al. (1999) indicated activated FAK-signaling during the development and progression of autoimmune-mediated nephritis in an animal model.

References Kanner SB, Reynolds AB, Vines RR, Parsons JT. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A. 1990 May;87(9):3328-32

Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992 Aug 20;358(6388):690-2

Hanks SK, Calalb MB, Harper MC, Patel SK. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8487-91

Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5192-6

André E, Becker-André M. Expression of an N-terminally truncated form of human focal adhesion kinase in brain. Biochem Biophys Res Commun. 1993 Jan 15;190(1):140-7

Schaller MD, Borgman CA, Parsons JT. Autonomous expression of a noncatalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK. Mol Cell Biol. 1993 Feb;13(2):785-91

Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10148-52

Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann Surg Oncol. 1994 Jan;1(1):18-27

Bellis SL, Miller JT, Turner CE. Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem. 1995 Jul 21;270(29):17437-41

Clark S, Muggli E, La Greca N, Dunlop ME. Increased phosphorylation of focal adhesion kinase in diabetic rat kidney glomeruli. Diabetologia. 1995 Oct;38(10):1131-7

Fiedorek FT Jr, Kay ES. Mapping of the focal adhesion kinase (Fadk) gene to mouse chromosome 15 and human chromosome 8. Mamm Genome. 1995 Feb;6(2):123-6

Ilić D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995 Oct 12;377(6549):539-44

Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995 Jul 1;55(13):2752-5



Polte TR, Hanks SK. Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10678-82

Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996 Aug;134(3):793-9

Harte MT, Hildebrand JD, Burnham MR, Bouton AH, Parsons JT. p130Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. J Biol Chem. 1996 Jun 7;271(23):13649-55

Jenq W, Cooper DR, Ramirez G. Integrin expression on cell adhesion function and up-regulation of P125FAK and paxillin in metastatic renal carcinoma cells. Connect Tissue Res. 1996;34(3):161-74

Shikano T, Haneda M, Togawa M, Kikkawa R. [Tyrosine phosphorylation of focal adhesion kinase (p125FAK) and paxillin in glomeruli from diabetic rats]. Nihon Jinzo Gakkai Shi. 1996 Feb;38(2):57-64

Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S. Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer. 1996 Oct 9;68(2):164-71

Morino N, Matsumoto T, Ueki K, Mimura T, Hamasaki K, Kanda H, Naruse T, Yazaki Y, Nojima Y. Glomerular overexpression and increased tyrosine phosphorylation of focal adhesion kinase p125FAK in lupus-prone MRL/MP-lpr/lpr mice. Immunology. 1999 Aug;97(4):634-40

Sieg DJ, Hauck CR, Schlaepfer DD. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci. 1999 Aug;112 ( Pt 16):2677-91

Zhang X, Chattopadhyay A, Ji QS, Owen JD, Ruest PJ, Carpenter G, Hanks SK. Focal adhesion kinase promotes phospholipase C-gamma1 activity. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9021-6

Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 1999 Apr 1;59(7):1655-64

Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000 May;2(5):249-56

Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem. 2000 May 26;275(21):16309-15

Chen G, McCormick TS, Hammerberg C, Ryder-Diggs S, Stevens SR, Cooper KD. Basal keratinocytes from uninvolved psoriatic skin exhibit accelerated spreading and focal adhesion kinase responsiveness to fibronectin. J Invest Dermatol. 2001 Dec;117(6):1538-45

Dourdin N, Bhatt AK, Dutt P, Greer PA, Arthur JS, Elce JS, Huttenlocher A. Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts. J Biol Chem. 2001 Dec 21;276(51):48382-8

Ma A, Richardson A, Schaefer EM, Parsons JT. Serine phosphorylation of focal adhesion kinase in interphase and mitosis: a possible role in modulating binding to p130(Cas). Mol Biol Cell. 2001 Jan;12(1):1-12

Abbi S, Ueda H, Zheng C, Cooper LA, Zhao J, Christopher R, Guan JL. Regulation of focal adhesion kinase by a novel protein inhibitor FIP200. Mol Biol Cell. 2002 Sep;13(9):3178-91

Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth. J Biol Chem. 2002 Sep 13;277(37):34391-400

Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG, Frame MC. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol. 2002 Aug;4(8):632-8

Cho SY, Klemke RL. Purification of pseudopodia from polarized cells reveals redistribution and activation of Rac through assembly of a CAS/Crk scaffold. J Cell Biol. 2002 Feb 18;156(4):725-36

Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 2002 Dec 2;21(23):6289-302

Hayashi I, Vuori K, Liddington RC. The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struct Biol. 2002 Feb;9(2):101-6

Huang D, Cheung AT, Parsons JT, Bryer-Ash M. Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. J Biol Chem. 2002 May 17;277(20):18151-60

Liu G, Guibao CD, Zheng J. Structural insight into the mechanisms of targeting and signaling of focal adhesion kinase. Mol Cell Biol. 2002 Apr;22(8):2751-60

Mori S, Takemoto M, Yokote K, Asaumi S, Saito Y. Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J Diabetes Complications. 2002 Jan-Feb;16(1):65-8

Rovin JD, Frierson HF Jr, Ledinh W, Parsons JT, Adams RB. Expression of focal adhesion kinase in normal and pathologic human prostate tissues. Prostate. 2002 Oct 1;53(2):124-32

Beggs HE, Schahin-Reed D, Zang K, Goebbels S, Nave KA, Gorski J, Jones KR, Sretavan D, Reichardt LF. FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies. Neuron. 2003 Oct 30;40(3):501-14

Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92

Kadaré G, Toutant M, Formstecher E, Corvol JC, Carnaud M, Boutterin MC, Girault JA. PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J Biol Chem. 2003 Nov 28;278(48):47434-40

Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, Yang X, Cance WG. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res. 2003 Jan;9(1):215-22

Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer. 2003 Sep-Oct;13(5):640-6



Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG. Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol. 2003 Mar;34(3):240-5

Xie Z, Sanada K, Samuels BA, Shih H, Tsai LH. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell. 2003 Aug 22;114(4):469-82

Zeng L, Si X, Yu WP, Le HT, Ng KP, Teng RM, Ryan K, Wang DZ, Ponniah S, Pallen CJ. PTP alpha regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration. J Cell Biol. 2003 Jan 6;160(1):137-46

Dunty JM, Gabarra-Niecko V, King ML, Ceccarelli DF, Eck MJ, Schaller MD. FERM domain interaction promotes FAK signaling. Mol Cell Biol. 2004 Jun;24(12):5353-68

Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery. 2004 May;135(5):555-62

Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, Inoue S, Yatabe Y, Takeda S, Nakao A. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol. 2004 Jul;41(1):104-11

Golubovskaya V, Kaur A, Cance W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim Biophys Acta. 2004 May 25;1678(2-3):111-25

Kim SJ, Park JW, Yoon JS, Mok JO, Kim YJ, Park HK, Kim CH, Byun DW, Lee YJ, Jin SY, Suh KI, Yoo MH. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study. J Korean Med Sci. 2004 Oct;19(5):710-5

Li W, Lee J, Vikis HG, Lee SH, Liu G, Aurandt J, Shen TL, Fearon ER, Guan JL, Han M, Rao Y, Hong K, Guan KL. Activation of FAK and Src are receptor-proximal events required for netrin signaling. Nat Neurosci. 2004 Nov;7(11):1213-21

Lightfoot HM Jr, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ, Cance WG. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat. 2004 Nov;88(2):109-16

Liu G, Beggs H, Jürgensen C, Park HT, Tang H, Gorski J, Jones KR, Reichardt LF, Wu J, Rao Y. Netrin requires focal adhesion kinase and Src family kinases for axon outgrowth and attraction. Nat Neurosci. 2004 Nov;7(11):1222-32

Livasy CA, Moore D, Cance WG, Lininger RA. Focal adhesion kinase overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):342-5

McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, Hodivala-Dilke K, Metzger D, Chambon P, Grant SG, Frame MC. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 2004 Dec 15;18(24):2998-3003

Palazzo AF, Eng CH, Schlaepfer DD, Marcantonio EE, Gundersen GG. Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science. 2004 Feb 6;303(5659):836-9

Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration,

increased cellularity, and poor prognosis. Cancer Res. 2004 May 1;64(9):3191-7

Ren XR, Ming GL, Xie Y, Hong Y, Sun DM, Zhao ZQ, Feng Z, Wang Q, Shim S, Chen ZF, Song HJ, Mei L, Xiong WC. Focal adhesion kinase in netrin-1 signaling. Nat Neurosci. 2004 Nov;7(11):1204-12

Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004 Oct;165(4):1087-95

Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M, Sabe H. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol. 2004 Jul 19;166(2):283-95

Ezratty EJ, Partridge MA, Gundersen GG. Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. Nat Cell Biol. 2005 Jun;7(6):581-90

Golubovskaya VM, Finch R, Cance WG. Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem. 2005 Jul 1;280(26):25008-21

Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer. 2005 Jan 20;113(3):372-8

Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36

Hanada M, Tanaka K, Matsumoto Y, Nakatani F, Sakimura R, Matsunobu T, Li X, Okada T, Nakamura T, Takasaki M, Iwamoto Y. Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis. Clin Exp Metastasis. 2005;22(6):485-94

Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res. 2005 Nov 1;65(21):9851-60

Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ, Cance W. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol. 2005 Oct;18(10):1289-94

Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68

Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW, Baba HA. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res. 2005;7(2):R194-203

Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol. 2005 Jun 20;169(6):941-52

Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X, Cance WG. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-



fluorouracil on the viability of melanoma cell lines. Melanoma Res. 2005 Oct;15(5):357-62

Tilghman RW, Slack-Davis JK, Sergina N, Martin KH, Iwanicki M, Hershey ED, Beggs HE, Reichardt LF, Parsons JT. Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J Cell Sci. 2005 Jun 15;118(Pt 12):2613-23

Braren R, Hu H, Kim YH, Beggs HE, Reichardt LF, Wang R. Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol. 2006 Jan 2;172(1):151-62

Canel M, Secades P, Rodrigo JP, Cabanillas R, Herrero A, Suarez C, Chiara MD. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3272-9

DiMichele LA, Doherty JT, Rojas M, Beggs HE, Reichardt LF, Mack CP, Taylor JM. Myocyte-restricted focal adhesion kinase deletion attenuates pressure overload-induced hypertrophy. Circ Res. 2006 Sep 15;99(6):636-45

Furuyama K, Doi R, Mori T, Toyoda E, Ito D, Kami K, Koizumi M, Kida A, Kawaguchi Y, Fujimoto K. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg. 2006 Feb;30(2):219-26

Gabriel B, zur Hausen A, Stickeler E, Dietz C, Gitsch G, Fischer DC, Bouda J, Tempfer C, Hasenburg A. Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome. Clin Cancer Res. 2006 Apr 15;12(8):2476-83

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15;12(16):4916-24

Hess AR, Hendrix MJ. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle. 2006 Mar;5(5):478-80

Huang D, Khoe M, Ilic D, Bryer-Ash M. Reduced expression of focal adhesion kinase disrupts insulin action in skeletal muscle cells. Endocrinology. 2006 Jul;147(7):3333-43

Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA, Schlaepfer DD. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006 Sep 28;25(44):5969-84

Peng X, Kraus MS, Wei H, Shen TL, Pariaut R, Alcaraz A, Ji G, Cheng L, Yang Q, Kotlikoff MI, Chen J, Chien K, Gu H, Guan JL. Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J Clin Invest. 2006 Jan;116(1):217-27

Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol. 2006 Jun;101(3):507-19

Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG, Golubovskaya VM. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem. 2007 Apr 27;282(17):12503-16

Hakim ZS, DiMichele LA, Doherty JT, Homeister JW, Beggs HE, Reichardt LF, Schwartz RJ, Brackhan J, Smithies O, Mack

CP, Taylor JM. Conditional deletion of focal adhesion kinase leads to defects in ventricular septation and outflow tract alignment. Mol Cell Biol. 2007 Aug;27(15):5352-64

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov 15;67(22):10976-83

Holzapfel K, Neuhofer W, Bartels H, Fraek ML, Beck FX. Role of focal adhesion kinase (FAK) in renal ischaemia and reperfusion. Pflugers Arch. 2007 Nov;455(2):273-82

Jacamo R, Jiang X, Lunn JA, Rozengurt E. FAK phosphorylation at Ser-843 inhibits Tyr-397 phosphorylation, cell spreading and migration. J Cell Physiol. 2007 Feb;210(2):436-44

Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, Muller WJ. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20302-7

Owen KA, Pixley FJ, Thomas KS, Vicente-Manzanares M, Ray BJ, Horwitz AF, Parsons JT, Beggs HE, Stanley ER, Bouton AH. Regulation of lamellipodial persistence, adhesion turnover, and motility in macrophages by focal adhesion kinase. J Cell Biol. 2007 Dec 17;179(6):1275-87

Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther. 2007;9(5):R112

Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog. 2007 Jun;46(6):488-96

Smit DJ, Gardiner BB, Sturm RA. Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer. 2007 Dec 15;121(12):2653-60

Vadali K, Cai X, Schaller MD. Focal adhesion kinase: an essential kinase in the regulation of cardiovascular functions. IUBMB Life. 2007 Nov;59(11):709-16

Yang YC, Ho TC, Chen SL, Lai HY, Wu JY, Tsao YP. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. BMC Cancer. 2007 Nov 20;7:216

Bagi CM, Roberts GW, Andresen CJ. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer. 2008 May 15;112(10):2313-21

Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, Cance WG, McGrady P, London WB. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res. 2008a Jun 1;14(11):3299-305

Beierle EA, Trujillo A, Nagaram A, Golubovskaya VM, Cance WG, Kurenova EV. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest. 2008b Mar;26(2):145-51

Canel M, Secades P, Garzón-Arango M, Allonca E, Suarez C, Serrels A, Frame M, Brunton V, Chiara MD. Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer. 2008 Apr 8;98(7):1274-84

Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, Fantoni A, Amicone L, Tripodi M. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res. 2008 Jan 1;314(1):143-52



de Heer P, Koudijs MM, van de Velde CJ, Aalbers RI, Tollenaar RA, Putter H, Morreau J, van de Water B, Kuppen PJ. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur J Surg Oncol. 2008 Nov;34(11):1253-61

Golubovskaya VM, Finch R, Kweh F, Massoll NA, Campbell-Thompson M, Wallace MR, Cance WG. p53 regulates FAK expression in human tumor cells. Mol Carcinog. 2008 May;47(5):373-82

Hu XW, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis. 2008 Dec;29(12):2369-76

Iwanicki MP, Vomastek T, Tilghman RW, Martin KH, Banerjee J, Wedegaertner PB, Parsons JT. FAK, PDZ-RhoGEF and ROCKII cooperate to regulate adhesion movement and trailing-edge retraction in fibroblasts. J Cell Sci. 2008 Mar 15;121(Pt 6):895-905

Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. Mol Cancer Res. 2008 Oct;6(10):1639-48

Kaneda T, Sonoda Y, Ando K, Suzuki T, Sasaki Y, Oshio T, Tago M, Kasahara T. Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett. 2008 Nov 8;270(2):354-61

Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD, Ilic D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008 Jan 18;29(1):9-22

Lipinski CA, Tran NL, Viso C, Kloss J, Yang Z, Berens ME, Loftus JC. Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts. J Neurooncol. 2008 Nov;90(2):181-9

Peng X, Wu X, Druso JE, Wei H, Park AY, Kraus MS, Alcaraz A, Chen J, Chien S, Cerione RA, Guan JL. Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice. Proc Natl Acad Sci U S A. 2008 May 6;105(18):6638-43

Playford MP, Vadali K, Cai X, Burridge K, Schaller MD. Focal adhesion kinase regulates cell-cell contact formation in epithelial cells via modulation of Rho. Exp Cell Res. 2008 Oct 15;314(17):3187-97

Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol. 2008 Nov;173(5):1551-65

Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther. 2008 Oct;7(10):3441-51

Franchini KG, Clemente CF, Marin TM. Focal adhesion kinase signaling in cardiac hypertrophy and failure. Braz J Med Biol Res. 2009 Jan;42(1):44-52

Gabriel B, Hasenburg A, Waizenegger M, Orlowska-Volk M, Stickeler E, zur Hausen A. Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study. Int J Gynecol Cancer. 2009 Oct;19(7):1221-5

Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE. Expression and clinical significance of focal adhesion kinase in the two distinct

histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res. 2009 Jun;15(2):173-81

Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009 Oct 1;125(7):1735-8

Hehlgans S, Lange I, Eke I, Cordes N. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother Oncol. 2009 Sep;92(3):371-8

Kobayashi H, Azumi M, Kimura Y, Sato K, Aoki N, Kimura S, Honma M, Iizuka H, Tateno M, Celis E. Focal adhesion kinase as an immunotherapeutic target. Cancer Immunol Immunother. 2009 Jun;58(6):931-40

Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009 Jan 15;69(2):466-74

Mariotti M, Castiglioni S, Maier JA. Inhibition of T24 human bladder carcinoma cell migration by RNA interference suppressing the expression of HD-PTP. Cancer Lett. 2009 Jan 8;273(1):155-63

Ozkal S, Paterson JC, Tedoldi S, Hansmann ML, Kargi A, Manek S, Mason DY, Marafioti T. Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues. Pathol Res Pract. 2009;205(11):781-8

Park AY, Shen TL, Chien S, Guan JL. Role of focal adhesion kinase Ser-732 phosphorylation in centrosome function during mitosis. J Biol Chem. 2009 Apr 3;284(14):9418-25

Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009 Feb;119(2):252-66

Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res. 2009 Jun 1;69(11):4750-9

Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 2009 Apr 15;69(8):3308-16

Sun T, Zhao N, Ni CS, Zhao XL, Zhang WZ, Su X, Zhang DF, Gu Q, Sun BC. Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK). Cancer Lett. 2009 Nov 28;285(2):141-50

van Miltenburg MH, Lalai R, de Bont H, van Waaij E, Beggs H, Danen EH, van de Water B. Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility. FASEB J. 2009 Oct;23(10):3482-93

Wang C, Yang R, Yue D, Zhang Z. Expression of FAK and PTEN in bronchioloalveolar carcinoma and lung adenocarcinoma. Lung. 2009 Mar-Apr;187(2):104-9

Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle. 2010 Mar 1;9(5):1005-15

Beierle EA, Ma X, Trujillo A, Kurenova EV, Cance WG, Golubovskaya VM. Inhibition of focal adhesion kinase and src



increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog. 2010 Mar;49(3):224-34

Chatzizacharias NA, Giaginis C, Zizi-Serbetzoglou D, Kouraklis GP, Karatzas G, Theocharis SE. Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas. 2010 Aug;39(6):930-6

Ding L, Sun X, You Y, Liu N, Fu Z. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival. Transl Res. 2010 Jul;156(1):45-52

Hayashi A, Aishima S, Inoue T, Nakata K, Morimatsu K, Nagai E, Oda Y, Tanaka M, Tsuneyoshi M. Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma. Hum Pathol. 2010 Jun;41(6):859-66

Lee J, Borboa AK, Chun HB, Baird A, Eliceiri BP. Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma. Cancer Res. 2010 Dec 15;70(24):10131-40

Lei K, Ye L, Yang Y, Wang GJ, Jiang QY, Jiang Y, Wei YQ, Deng HX. RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice. J Biomed Nanotechnol. 2010 Jun;6(3):272-8

Michailidi C, Giaginis C, Stolakis V, Alexandrou P, Klijanienko J, Delladetsima I, Chatzizacharias N, Tsourouflis G, Theocharis S. Evaluation of FAK and Src expression in human benign and malignant thyroid lesions. Pathol Oncol Res. 2010 Dec;16(4):497-507

Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31;30(13):1566-76

Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, Quaranta V, Massion PP. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene. 2010 Dec 2;29(48):6331-42

Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol. 2010 Dec;41(12):1664-73

Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P, Batra SK. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010 Oct 21;29(42):5741-54

Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci. 2010 Apr 1;123(Pt 7):1007-13

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May 3;120(5):1515-23

Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP, Capozza F. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res. 2010 Oct 1;70(19):7489-99

Yom CK, Noh DY, Kim WH, Kim HS. Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res Treat. 2011 Aug;128(3):647-55

Yui Y, Itoh K, Yoshioka K, Naka N, Watanabe M, Hiraumi Y, Matsubara H, Watanabe K, Sano K, Nakahata T, Adachi S. Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8. Clin Exp Metastasis. 2010 Dec;27(8):619-30

Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3725-30

Wang GJ, Ma YP, Yang Y, Zhang N, Wang W, Liu SY, Chen LJ, Jiang Y, Zhao X, Wei YQ, Deng HX. RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human malignant glioma xenograft in nude mice. Cell Biol Int. 2011 Aug 1;35(8):841-8

This article should be referenced as such:

Schwock J, Dhani N. PTK2 (PTK2 protein tyrosine kinase 2). Atlas Genet Cytogenet Oncol Haematol. 2011; 15(10):854-866.

OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section

Documents